Pharmacopeia Completes Acquisition of Oxford s Software Subsidiaries | GenomeWeb

NEW YORK, Sept 6 - Pharmacopeia (Nasdaq: PCOP) said Wednesday it had completed the acquisition of the software subsidiaries of Oxford Molecular Group of Oxford, UK.

The deal, which was valued at about $27 million, including cash and the assumption of certain liabilities, includes Oxford’s GCG bioinformatics software line and its RS3 cheminformatics products.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.